Vanguard Group
BCLI

Vanguard Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Vanguard Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,724
Closed -$31.1K – 4355
2025
Q2 		$31.1K Hold
27,724
– – ﹤0.01% 4223
2025
Q1 		$34.9K Sell
27,724
-50,717
-65% -$89.8K ﹤0.01% 4218
2024
Q4 		$178K Sell
78,441
-22,268
-22% -$41.1K ﹤0.01% 4117
2024
Q3 		$347K Hold
100,709
– – ﹤0.01% 4051
2024
Q2 		$511K Buy
100,709
+7,309
+8% +$54.8K ﹤0.01% 3994
2024
Q1 		$791K Sell
93,400
-1,487
-2% -$8.18K ﹤0.01% 3886
2023
Q4 		$389K Hold
94,887
– – ﹤0.01% 4104
2023
Q3 		$285K Hold
94,887
– – ﹤0.01% 4193
2023
Q2 		$2.93M Sell
94,887
-349
-0.4% -$14.5K ﹤0.01% 3531
2023
Q1 		$4.71M Hold
95,236
– – ﹤0.01% 3333
2022
Q4 		$2.34M Buy
95,236
+43
+0% +$1.61K ﹤0.01% 3606
2022
Q3 		$6.31M Hold
95,193
– – ﹤0.01% 3198
2022
Q2 		$3.94M Buy
95,193
+453
+0.5% +$20.4K ﹤0.01% 3503
2022
Q1 		$4.78M Sell
94,740
-631
-0.7% -$31K ﹤0.01% 3551
2021
Q4 		$5.72M Sell
95,371
-124
-0.1% -$6.1K ﹤0.01% 3531
2021
Q3 		$4.73M Buy
95,495
+1,307
+1% +$68.8K ﹤0.01% 3699
2021
Q2 		$5.37M Buy
94,188
+5,491
+6% +$293K ﹤0.01% 3558
2021
Q1 		$5.1M Buy
88,697
+2,358
+3% +$178K ﹤0.01% 3521
2020
Q4 		$5.86M Buy
86,339
+6,216
+8% +$847K ﹤0.01% 3287
2020
Q3 		$20.3M Sell
80,123
-10,282
-11% -$2.11M ﹤0.01% 2451
2020
Q2 		$15.2M Buy
90,405
+9,320
+11% +$1M ﹤0.01% 2554
2020
Q1 		$5.64M Buy
81,085
+29,614
+58% +$2.31M ﹤0.01% 2920
2019
Q4 		$3.3M Buy
51,471
+346
+0.7% +$20.1K ﹤0.01% 3302
2019
Q3 		$2.99M Buy
51,125
+5,009
+11% +$295K ﹤0.01% 3308
2019
Q2 		$2.73M Hold
46,116
– – ﹤0.01% 3380
2019
Q1 		$3M Buy
46,116
+342
+0.7% +$19.5K ﹤0.01% 3329
2018
Q4 		$2.44M Sell
45,774
-508
-1% -$25K ﹤0.01% 3313
2018
Q3 		$2.65M Hold
46,282
– – ﹤0.01% 3439
2018
Q2 		$2.71M Buy
46,282
+947
+2% +$55.7K ﹤0.01% 3408
2018
Q1 		$2.14M Buy
45,335
+84
+0.2% +$4.23K ﹤0.01% 3436
2017
Q4 		$2.66M Buy
45,251
+79
+0.2% +$4.72K ﹤0.01% 3337
2017
Q3 		$2.79M Buy
45,172
+1,365
+3% +$88.3K ﹤0.01% 3306
2017
Q2 		$2.73M Buy
43,807
+1,177
+3% +$72.5K ﹤0.01% 3289
2017
Q1 		$2.72M Buy
42,630
+3,886
+10% +$202K ﹤0.01% 3280
2016
Q4 		$1.48M Buy
38,744
+693
+2% +$24K ﹤0.01% 3460
2016
Q3 		$1.36M Buy
38,051
+5,260
+16% +$197K ﹤0.01% 3499
2016
Q2 		$1.19M Buy
32,791
+413
+1% +$14.5K ﹤0.01% 3559
2016
Q1 		$1.3M Buy
32,378
+1,509
+5% +$55.4K ﹤0.01% 3525
2015
Q4 		$1.32M Buy
30,869
+859
+3% +$35.4K ﹤0.01% 3540
2015
Q3 		$1.03M Buy
30,010
+2,130
+8% +$100K ﹤0.01% 3619
2015
Q2 		$1.51M Buy
27,880
+6,337
+29% +$378K ﹤0.01% 3534
2015
Q1 		$1.44M Buy
+21,543
New +$1.36M ﹤0.01% 3526

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Vanguard Group's BCLI Position: Q3 2025 in Review

Vanguard Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 27,724 shares — an estimated $31.1K sold.

Vanguard Group first reported a position in BCLI in Q1 2015 and held it in 42 quarters. The position peaked at $20.3M in Q3 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Vanguard Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Vanguard Group sold 27,724 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $31.1K.
  • Vanguard Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 42 quarters.
  • Vanguard Group's BRAINSTORM CELL THERAPUTC position peaked at $20.3M in Q3 2020.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.